NCR2 Antibody

What is NCR2 and why is it significant in immunological research?

NCR2, also known as NKp44, is one of the Natural Cytotoxicity Receptors (NCRs) expressed almost exclusively by Natural Killer (NK) cells. It plays a critical role in triggering NK-mediated killing of tumor cell lines, making it a significant target for cancer immunotherapy research. Unlike other NCRs (NKp30 and NKp46), NKp44 has no identified rodent ortholog, which has important implications for translational research. The receptor is characterized by the presence of one extracellular V-like immunoglobulin domain and is synthesized as a 276 amino acid precursor . Understanding NCR2's structure and function provides insights into innate immune surveillance mechanisms and potential therapeutic targets for cancer treatment.

What are the key structural features of human NCR2/NKp44?

Human NCR2/NKp44 is a 44 kDa type I transmembrane glycoprotein with distinctive structural elements that contribute to its function. The protein is synthesized as a 276 amino acid precursor containing:

• A 21 amino acid signal sequence

• A 171 amino acid extracellular region with one V-like immunoglobulin domain

• A 21 amino acid transmembrane segment

• A 63 amino acid cytoplasmic tail

Alternative splicing in both the cytoplasmic tail and extracellular region generates multiple isoforms, though the Ig-like region remains unaffected across these variants. The receptor forms a physical association with the ITAM-bearing accessory protein DAP12 through a charged residue in its transmembrane domain, which is essential for signal transduction . This molecular structure allows NCR2 to function as an activating receptor that triggers cytotoxicity in NK cells.

How does NCR2 expression differ between resting and activated NK cells?

NCR2/NKp44 displays a distinctive expression pattern that differentiates it from other natural cytotoxicity receptors. While it is absent on resting NK cells, expression is significantly upregulated following activation with interleukin-2 (IL-2). This activation-induced expression pattern makes NCR2 a valuable marker for activated NK cells in research applications . When studying NK cell activation, researchers can monitor NCR2 expression as an indicator of functional status. The regulated expression suggests NCR2 may play a specialized role in activated NK cell functions rather than participating in baseline NK surveillance activities, which has implications for experimental design when studying NK cell biology.

What applications are most suitable for NCR2 antibodies in research?

NCR2 antibodies have been validated for multiple experimental applications, each providing distinct insights into NCR2 biology. Based on manufacturer data, the following applications have demonstrated reliability:

Optimal dilutions should be determined by each laboratory for specific applications, as results may vary depending on sample type and experimental conditions .

How can NCR2 antibodies be employed in functional assays studying NK cell activity?

NCR2 antibodies offer valuable tools for investigating NK cell functional responses. Mouse anti-human NKp44/NCR2 monoclonal antibodies have been demonstrated to induce interferon-gamma (IFN-gamma) secretion in IL-2 activated human NK cells in a dose-dependent manner. The typical effective dose (ED50) for this response ranges from 0.05-0.2 μg/mL, as measured using IFN-gamma ELISA kits .

For conducting such functional assays:

• Isolate peripheral blood mononuclear cells (PBMCs)

• Activate NK cells with recombinant human IL-2 (500-1000 ng/mL) for 24-48 hours

• Treat activated NK cells with varying concentrations of anti-NCR2 antibody

• Measure IFN-gamma secretion in culture supernatants after appropriate incubation time

• Analyze dose-response relationship to determine optimal antibody concentration

Additionally, antibody-mediated receptor ligation can be used in redirected killing assays, where ligation of NKp44 with specific antibodies results in phosphorylation of DAP12 and subsequent activation of target cell lysis . These methods provide insights into NCR2's role in NK cell effector functions.

What are the optimal storage conditions for maintaining NCR2 antibody activity?

Proper storage of NCR2 antibodies is critical for maintaining their functionality over time. Based on manufacturer recommendations, the following storage guidelines should be observed:

• Long-term storage: Store at -20°C to -70°C for up to 12 months from the date of receipt in the supplied format

• Short-term storage: Store at 2-8°C under sterile conditions for up to 1 month after reconstitution

• Extended storage after reconstitution: Store at -20°C to -70°C under sterile conditions for up to 6 months

To preserve antibody activity:

• Use a manual defrost freezer

• Avoid repeated freeze-thaw cycles, which can significantly reduce antibody functionality

• Aliquot reconstituted antibodies to minimize freeze-thaw events

• Ensure sterile conditions during handling to prevent contamination

These storage recommendations apply to most commercial NCR2 antibodies, though specific guidelines may vary slightly between manufacturers and antibody formats.

How can NCR2 antibodies be utilized to investigate the signaling pathway of activated NK cells?

Investigating NCR2-mediated signaling pathways requires strategic experimental design that captures both proximal and distal signaling events. NCR2 antibodies serve as valuable tools in this process through several methodological approaches:

• Immunoprecipitation coupled with phospho-specific Western blot analysis:

  • Stimulate NK cells with anti-NCR2 antibodies

  • Immunoprecipitate DAP12 (the adaptor protein that associates with NCR2)

  • Perform Western blot with phospho-tyrosine antibodies to detect DAP12 phosphorylation following NCR2 engagement

• Phospho-flow cytometry:

  • Use anti-NCR2 antibodies as stimulating agents

  • Fix and permeabilize cells at various time points

  • Stain with antibodies against phosphorylated signaling molecules (e.g., phospho-SYK, phospho-ZAP70)

  • Analyze by flow cytometry to track signaling kinetics in NK cell populations

• Calcium flux assays:

  • Load NK cells with calcium-sensitive dyes

  • Stimulate with anti-NCR2 antibodies

  • Monitor intracellular calcium levels as an indicator of proximal signaling events

These approaches help delineate how NCR2 engagement triggers cytotoxicity in NK cells and could identify potential targets for therapeutic intervention in cancer immunotherapy research.

What methodologies are recommended for studying NCR2 interactions with its ligands?

Studying NCR2 interactions with its putative ligands requires specialized methodologies that preserve the native conformation of the receptor while providing quantitative binding data. Several experimental approaches are recommended:

• Recombinant protein binding assays:

  • Generate recombinant NCR2-Fc fusion proteins

  • Test binding to potential ligand-expressing cells via flow cytometry

  • Confirm specificity using anti-NCR2 antibodies as blocking agents

• Surface Plasmon Resonance (SPR):

  • Immobilize purified NCR2 protein on sensor chips

  • Flow potential ligands across the surface

  • Measure binding kinetics and affinity constants

  • Use anti-NCR2 antibodies to confirm proper receptor orientation and accessibility

• Proximity ligation assays in tissue sections:

  • Apply anti-NCR2 antibodies together with antibodies against potential ligands

  • Use species-specific secondary antibodies linked to complementary oligonucleotides

  • Visualize protein-protein interactions as fluorescent spots when proteins are in close proximity

• Bio-Layer Interferometry:

  • Immobilize biotinylated NCR2 on streptavidin sensors

  • Measure real-time binding to putative ligands

  • Calculate association and dissociation rates

These methodologies provide complementary data on NCR2-ligand interactions and should be selected based on specific research questions and available resources.

How can researchers address potential cross-reactivity issues when using NCR2 antibodies?

Cross-reactivity remains a significant challenge when working with antibodies, potentially leading to misinterpreted results. For NCR2 antibodies, researchers should implement comprehensive validation strategies:

Thorough validation improves data reliability and facilitates accurate interpretation of experimental results involving NCR2.

What are common challenges when detecting NCR2 in Western blot applications and how can they be addressed?

Western blot detection of NCR2 presents several technical challenges that can be methodically addressed:

• Variable glycosylation affecting apparent molecular weight:

  • NCR2 is a glycoprotein that may appear at multiple molecular weights (typically around 44 kDa)

  • Treatment with deglycosylation enzymes prior to electrophoresis can reveal the core protein size

  • Include positive control lysates from NK-92 human natural killer lymphoma cell line

• Low expression levels in certain samples:

  • Ensure NK cells are properly activated with IL-2 to upregulate NCR2 expression

  • Increase protein loading amounts specifically for NCR2 detection

  • Consider using more sensitive detection methods (e.g., enhanced chemiluminescence substrates)

• Inefficient protein transfer:

  • Optimize transfer conditions specifically for transmembrane proteins

  • Consider semi-dry versus wet transfer methods based on protein size

  • Use PVDF membranes for improved protein retention and signal-to-noise ratio

• High background signal:

  • Implement more stringent blocking conditions (5% BSA or milk in TBST)

  • Increase washing duration and frequency between antibody incubations

  • Optimize primary antibody dilution (typically 1:200-1:2000 for NCR2)

Following these optimization strategies can significantly improve NCR2 detection sensitivity and specificity in Western blot applications.

How should researchers interpret varying NCR2 expression levels across different NK cell populations?

Interpreting NCR2 expression heterogeneity requires consideration of multiple biological and technical factors:

• Activation state assessment:

  • Correlate NCR2 expression with other activation markers (CD69, CD25)

  • Track activation duration, as expression kinetics may vary among donors

  • Consider IL-2 concentration effects, as NCR2 upregulation is dose-dependent

• Donor variability considerations:

  • Establish baseline expression ranges across multiple healthy donors

  • Account for age, sex, and genetic background as potential variables

  • Consider pathological conditions that might affect NK cell receptor repertoires

• Technical normalization approaches:

  • Use quantitative flow cytometry with standardized beads for absolute receptor quantification

  • Report data as molecules of equivalent soluble fluorochrome (MESF) for cross-experimental comparison

  • Include consistent positive controls in each experiment

• Functional correlation analysis:

  • Correlate NCR2 expression levels with NK cell functional readouts (cytotoxicity, cytokine production)

  • Sort NK cells based on NCR2 expression levels to test functional differences

  • Consider receptor co-expression patterns rather than analyzing NCR2 in isolation

This comprehensive interpretation approach accounts for biological variability while maintaining scientific rigor in data analysis.

What factors influence the efficacy of NCR2 antibodies in functional assays?

Multiple factors can affect the performance of NCR2 antibodies in functional applications, requiring careful experimental consideration:

• Antibody characteristics:

  • Clone specificity: Different antibody clones (e.g., 253415, 253422) may target distinct epitopes with varying functional outcomes

  • Antibody format: Whole IgG versus F(ab')2 or Fab fragments may produce different signaling effects

  • Concentration optimization: Functional assays typically require precise antibody titration, with effective doses for IFN-γ induction typically ranging from 0.05-0.2 μg/mL

• NK cell preparation variables:

  • Activation protocol: Duration and concentration of IL-2 treatment affect NCR2 expression levels

  • Donor variability: Genetic factors influence receptor expression and functional responses

  • Cell viability: Suboptimal viability can significantly reduce functional readouts

• Experimental conditions:

  • Plate coating for immobilized antibody assays: Coating buffer, concentration, and time affect antibody presentation

  • Secondary crosslinking: Addition of secondary antibodies may enhance receptor clustering and signaling

  • Timing of measurements: Cytokine production peaks at different timepoints depending on the specific cytokine

• Readout systems:

  • Direct versus indirect measurements: Cytotoxicity assays versus cytokine production may yield different sensitivity

  • Assay sensitivity: ELISA detection limits for IFN-γ can affect ability to detect subtle functional differences

  • Single-cell versus bulk analysis: Flow cytometry-based functional assays provide cellular resolution that bulk assays lack

Controlling these variables and including appropriate controls enables more reproducible and interpretable functional data when working with NCR2 antibodies.

How are NCR2 antibodies being employed in cancer immunotherapy research?

NCR2 antibodies are enabling several innovative approaches in cancer immunotherapy research, primarily focusing on enhancing NK cell-mediated tumor recognition and elimination:

• Bispecific antibody development:

  • Engineering bispecific antibodies that simultaneously engage NCR2 on NK cells and tumor-associated antigens

  • Redirecting NK cytotoxicity specifically toward tumor cells

  • Testing various antibody formats (BiTEs, DARTs, TandAbs) for optimal efficacy

• Characterizing NCR2 ligand expression in tumor microenvironments:

  • Using NCR2-Fc fusion proteins to identify tumor types expressing NCR2 ligands

  • Correlating ligand expression with clinical outcomes and NK cell infiltration

  • Developing strategies to upregulate NCR2 ligands on resistant tumors

• Checkpoint modulation strategies:

  • Investigating whether NCR2 signaling can overcome inhibitory signals in the tumor microenvironment

  • Combining NCR2-targeting approaches with established checkpoint inhibitors

  • Measuring synergistic effects on NK cell activation and tumor killing

• CAR-NK engineering:

  • Incorporating NCR2 signaling domains into chimeric antigen receptors for NK cells

  • Comparing NCR2-based signaling domains with other activating receptor domains

  • Optimizing persistence and functionality of NCR2-CAR NK cells in vivo

These research directions demonstrate how NCR2 antibodies serve as both investigative tools and potential therapeutic agents in the evolving landscape of cancer immunotherapy.

What are the methodological considerations for studying NCR2 in tissue-resident NK cells?

Studying NCR2 in tissue-resident NK cells presents unique methodological challenges that require specialized approaches:

• Tissue processing optimization:

  • Develop gentle enzymatic digestion protocols that preserve surface receptor integrity

  • Compare mechanical versus enzymatic isolation methods for receptor expression artifacts

  • Implement immediate ex vivo staining before receptor modulation occurs

• Multiplexed imaging approaches:

  • Apply multiplexed immunofluorescence to simultaneously detect NCR2, tissue-resident markers, and activation status

  • Utilize spectral unmixing to resolve multiple fluorophores in tissues with high autofluorescence

  • Consider tissue clearing techniques for three-dimensional visualization of NK cell distributions

• Single-cell analysis integration:

  • Combine flow cytometry-based phenotyping with single-cell RNA sequencing

  • Correlate protein-level NCR2 expression with transcriptional profiles

  • Analyze receptor isoform expression unique to tissue-resident populations

• In situ functional assessment:

  • Develop tissue explant models that maintain microenvironmental influences

  • Apply anti-NCR2 antibodies directly to tissue sections to measure local activation

  • Correlate NCR2 expression with tissue-specific functional markers

These methodological considerations acknowledge the specialized biology of tissue-resident NK cells, which may display different NCR2 expression patterns and functions compared to circulating NK cells, particularly in inflammatory environments .

How can researchers effectively compare data between different commercial NCR2 antibody clones?

Comparative analysis between different commercial NCR2 antibody clones requires systematic standardization approaches:

• Epitope mapping standardization:

  • Determine the exact epitopes recognized by different clones (e.g., 253415, 253422, 7A7D4G11)

  • Create epitope overlap maps to predict potential differences in functionality

  • Consider how epitope location may affect receptor-ligand interactions or signaling capacity

• Side-by-side functional comparisons:

  • Test multiple clones simultaneously under identical experimental conditions

  • Measure dose-response curves for each clone in functional assays (e.g., IFN-γ induction)

  • Calculate relative potency indices to quantitatively compare clone efficacy

• Cross-validation with recombinant proteins:

  • Develop standard ELISA assays using recombinant NCR2 protein

  • Determine binding affinity (Kd) values for each antibody clone

  • Correlate binding affinity with functional potency

• Reporting standards implementation:

  • Document complete antibody information in publications (clone, manufacturer, catalog number, lot)

  • Include validation data demonstrating specificity for each application

  • Share raw data in repositories to facilitate meta-analysis across studies

This systematic approach enables more meaningful comparisons between studies using different NCR2 antibody clones and builds a more coherent understanding of NCR2 biology across the research community.